Patent US5635531A successfully refreshed from Google Patents.
US5635531A
Expired / Lapsed
US
⏱️ 0.0 years remaining
3'-aminocarbonyloxy paclitaxels
Assignee: Bristol Myers Squibb Co
•
Filing: 1996-07-08
•
Granted: 1997-06-03
•
Expires: 2016-07-08
Abstract
Abstract The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.
Inventors
- 👤 Shu-Hui Chen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 21:51
CPC Classifications
C; C07; C07D; C07D407/00; C07D407/02; C07D407/12; C07D305/00; C07D305/14
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
360 words
A compound of formula I, or a pharmaceutically acceptable salt thereof ##STR59## wherein R 1 is hydroxy, --OC(O)R x or --OC(O)OR x ; R 2 is hydrogen, hydroxy, methoxy, --OC(O)R x or --OC(O)OR x ; R 2' is hydrogen, hydroxy or fluoro; R 6' is hydrogen or hydroxy; R 6 is hydrogen, or R 2 and R 6 together can form oxirane ring or a bond; R 3 is hydrogen, hydroxy, C 1-6 alkyloxy, --OCONR 14 R 15 , --OC(O)R x or --OC(O)OR x ; R 8 is methyl or hydroxymethyl, or R 8 and R 2 together form cyclopropane ring; R 9 is hydroxy or --OC(O)R x ; with the proviso that when R 8 and R 2 form cyclopropane ring, R 2' is hydrogen; when R 2 and R 6 form oxirane ring or double bond, R 2' and R 6' are hydrogen; when R 2 is hydroxy, methoxy, --OC(O)R x or --OC(O)OR x , R 2' is hydrogen; when R 2' is fluoro, R 2 is hydrogen; one of R 7 or R 7' is hydrogen and the other is hydroxy, --OC(O)R x or --OC(O)OR x , or R 7 and R 7' together form an oxo group; R 14 and R 15 are independently C 1-6 alkyl, hydrogen, aryl or substituted aryl; R 4 and R 5 are independently C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or --Z--R 10 ; Z is a direct bond, C 1-6 alkyl or C 2-6 alkenyl; R 10 is aryl, substituted aryl, C 3-6 cycloalkyl or heteroaryl; R 11 is --OC(O)R y or --OC(O)OR y ; R 12 is hydrogen or hydroxy; R y is C 3-6 cycloalkyl or C 1-6 alkyl; R x is C 3-6 cycloalkyl, C 2-6 alkenyl or C 1-6 alkyl, all are optionally substituted with one to six same or different halogen atoms; or R x is a radical of the formula ##STR60## wherein D is a bond or C 1-6 alkyl; and R a , R b and R c are independently hydrogen, nitro, cyano, azido, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, halogen, C 1-6 alkyl, hydroxy or C 1-6 alkoxy.
Claim 2
Dependent Claim
360 words
A compound of formula I, or a pharmaceutically acceptable salt thereof ##STR59## wherein R 1 is hydroxy, --OC(O)R x or --OC(O)OR x ; R 2 is hydrogen, hydroxy, methoxy, --OC(O)R x or --OC(O)OR x ; R 2' is hydrogen, hydroxy or fluoro; R 6' is hydrogen or hydroxy; R 6 is hydrogen, or R 2 and R 6 together can form oxirane ring or a bond; R 3 is hydrogen, hydroxy, C 1-6 alkyloxy, --OCONR 14 R 15 , --OC(O)R x or --OC(O)OR x ; R 8 is methyl or hydroxymethyl, or R 8 and R 2 together form cyclopropane ring; R 9 is hydroxy or --OC(O)R x ; with the proviso that when R 8 and R 2 form cyclopropane ring, R 2' is hydrogen; when R 2 and R 6 form oxirane ring or double bond, R 2' and R 6' are hydrogen; when R 2 is hydroxy, methoxy, --OC(O)R x or --OC(O)OR x , R 2' is hydrogen; when R 2' is fluoro, R 2 is hydrogen; one of R 7 or R 7' is hydrogen and the other is hydroxy, --OC(O)R x or --OC(O)OR x , or R 7 and R 7' together form an oxo group; R 14 and R 15 are independently C 1-6 alkyl, hydrogen, aryl or substituted aryl; R 4 and R 5 are independently C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, or --Z--R 10 ; Z is a direct bond, C 1-6 alkyl or C 2-6 alkenyl; R 10 is aryl, substituted aryl, C 3-6 cycloalkyl or heteroaryl; R 11 is --OC(O)R y or --OC(O)OR y ; R 12 is hydrogen or hydroxy; R y is C 3-6 cycloalkyl or C 1-6 alkyl; R x is C 3-6 cycloalkyl, C 2-6 alkenyl or C 1-6 alkyl, all are optionally substituted with one to six same or different halogen atoms; or R x is a radical of the formula ##STR60## wherein D is a bond or C 1-6 alkyl; and R a , R b and R c are independently hydrogen, nitro, cyano, azido, amino, C 1-6 alkylamino, di-C 1-6 alkylamino, halogen, C 1-6 alkyl, hydroxy or C 1-6 alkoxy.
Claim 3
Dependent Claim
34 words
A compound as claimed claim 1 which has the formula ##STR61## in which R 17 is methyl or hydrogen; and R 3 , R 4 and R 5 are as defined in claim 1.
Claim 4
Dependent Claim
36 words
A compound as claimed in claim 2 in which R 3 is hydroxy or acetyloxy, R 4 is C 1-6 alkyl or C 3-6 cycloalkyl, R 5 is furyl or phenyl, and R 17 is hydrogen.
Claim 5
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is acetyloxy, R 4 is t-butyl, and R 5 is phenyl.
Claim 6
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is acetyloxy, R 4 is t-butyl, and R 5 is 2-furyl.
Claim 7
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is hydroxy, R 4 is t-butyl, and R 5 is phenyl.
Claim 8
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is hydroxy, R 4 is t-butyl, and R 5 is 2-furyl.
Claim 9
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is acetyloxy, R 4 is isopropyl, and R 5 is phenyl.
Claim 10
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is acetyloxy, R 4 is isopropyl, and R 5 is 2-furyl.
Claim 11
Dependent Claim
22 words
A compound as claimed in claim 3 in which R 3 is acetyloxy, R 4 is cyclobutyl, and R 5 is 2-furyl.
Claim 12
Dependent Claim
37 words
A compound as claimed in claim 2 in which R 3 is hydroxy or acetyloxy, R 4 is C 1-6 alkyl or C 3-6 cycloalkyl, and R 5 is furyl or phenyl, and R 17 is methyl.
Claim 13
Dependent Claim
22 words
A compound as claimed in claim 11 in which R 3 is acetyloxy, R 4 is t-butyl, and R 5 is 2-furyl.
Claim 14
Dependent Claim
22 words
A compound as claimed in claim 11 in which R 3 is acetyloxy, R 4 is cyclobutyl, and R 5 is 2-furyl.
Claim 15
Dependent Claim
23 words
A pharmaceutical formulation which comprises an antitumor effective amount of a compound of formula I as claimed in any one of claims 1-13.
Claim 16
Independent Claim
34 words
A method for inhibiting tumor growth in a mammalian host which comprises administering to said mammal a tumor-growth inhibiting amount of a compound of formula I as claimed in any one of claims 1-13.
References Cited (Backward Citations)
US4814470A
Cited
US4942184A
Cited
US4960790A
Cited
EP0400971A2
Cited
US5059699A
Cited
US5539103A
Cited
WO1993006093A1
Cited
US5229526A
Cited
US5227400A
Cited
US5466834A
Cited
US5489601A
Cited
US5283253A
Cited
EP0552041A2
Cited
EP0558959A1
Cited
US5272171A
Cited
US5352806A
Cited
US5294637A
Cited
EP0582469A2
Cited
US5319112A
Cited
EP0590267A2
Cited
US5478854A
Cited
WO1994008984A1
Cited
EP0600517A1
Cited
WO1994013655A1
Cited
WO1994014787A1
Cited
EP0604910A1
Cited
US5338872A
Cited
US5254580A
Cited
WO1994017050A1
Cited
WO1994020485A1
Cited
EP0617034A1
Cited
EP0634492A1
Cited
US5468769A
Cited
US5395850A
Cited
US5489589A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-06-02 | 2000-12-02 | 2001-06-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-06-02 | 2004-12-02 | 2005-06-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-06-02 | 2008-12-02 | 2009-06-03 | $7700.00 | Window Closed / Lapsed |